Ignite Creation Date:
2024-05-05 @ 11:00 PM
Last Modification Date:
2024-10-26 @ 10:27 AM
Study NCT ID:
NCT01239849
Status:
UNKNOWN
Last Update Posted:
2010-11-15
First Post:
2010-11-10
Brief Title:
Korean AMADEUS Study
Sponsor:
The Catholic University of Korea
Organization:
The Catholic University of Korea
Study Overview
Official Title:
A Multicenter Eight Weeks Treatment Single Step Titration Open Label Study Assessing the Percentage of Korean Diabetic Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Dose 10mg 20mg 40mg
Status:
UNKNOWN
Status Verified Date:
2009-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Because Diabetes Mellitus is one of the major risk factors for CV disease and lots of related evidences have been published including CARDS study that showed definite benefit of statin treatment in DM patients and influenced ADA guideline NCEP ATP III update However there are large unmet medical needs for DM patients who dont reach their target LDL-C level defined NCEPT ATP III update because of physicians usually start with the lowest dose of statin and then titrate to the goal Thus we are curious about changing our prescription pattern into more tailored way selecting starting dose based on the individual risk factors and concomitant status will impact the goal achieving rate for DM patients Besides that we are going to find out preliminary data about other markers change small dense LDL and adiponectine Small dense LDL-C is more inflammatory and atherogenic LDL-C that may explain the impact of triglyceride Adiponectin is another good marker related with obesity and metabolic syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None